Profound Medical (NASDAQ:PROF) Announces Quarterly Earnings Results

Profound Medical (NASDAQ:PROF) released its quarterly earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.11, Zacks reports. The company had revenue of $4.18 million during the quarter, compared to the consensus estimate of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%.

Profound Medical Price Performance

Shares of NASDAQ:PROF opened at $6.86 on Friday. The company has a market cap of $206.07 million, a P/E ratio of -5.12 and a beta of 0.78. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. Profound Medical has a 52 week low of $5.63 and a 52 week high of $11.42. The business has a fifty day simple moving average of $7.03 and a 200-day simple moving average of $7.61.

Analysts Set New Price Targets

Separately, Raymond James raised Profound Medical to a “strong-buy” rating in a research report on Saturday, November 9th.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.